- Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Herbst, R.S., Johnson, D.H., Mininberg, E., Carbone, D.P., Henderson, T., Kim, E.S., Blumenschein, G., Lee, J.J., Liu, D.D., Truong, M.T., Hong, W.K., Tran, H., Tsao, A., Xie, D., Ramies, D.A., Mass, R., Seshagiri, S., Eberhard, D.A., Kelley, S.K., Sandler, A. J. Clin. Oncol. (2005)